Lifevantage (NASDAQ:LFVN) Releases FY 2026 Earnings Guidance

Key Points

• FY 2026 guidance below expectations: Lifevantage guided to EPS of $0.60 and revenue of $185.0M, both under the consensus estimates of $0.67 EPS and $193.0M revenue.
• Recent quarter missed estimates as well, reporting $0.12 EPS versus $0.16 expected and revenue of $43.72M versus $47.77M, while analysts project about $0.65 EPS for the current year.
• Insider buying: Director Judd Dayton purchased 18,097 shares at an average price of $4.63 (a 34.96% increase in his ownership); insiders now own about 21.95% of the company.

Lifevantage (NASDAQ:LFVN - Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.600-0.600 for the period, compared to the consensus estimate of 0.670. The company issued revenue guidance of $185.0 million-$185.0 million, compared to the consensus revenue estimate of $193.0 million.

Lifevantage Stock Performance

LFVN stock opened at $6.00 on Thursday. Lifevantage has a fifty-two week low of $3.90 and a fifty-two week high of $15.00. The stock has a fifty day moving average of $4.70 and a 200-day moving average of $5.81. The company has a market capitalization of $76.86 million, a price-to-earnings ratio of 10.00 and a beta of 0.52.

Lifevantage (NASDAQ:LFVN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.04). Lifevantage had a net margin of 3.74% and a return on equity of 29.59%. The company had revenue of $43.72 million during the quarter, compared to analysts' expectations of $47.77 million. Equities analysts predict that Lifevantage will post 0.65 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on LFVN. Loop Capital set a $5.00 target price on shares of Lifevantage in a research report on Thursday, February 5th. Lake Street Capital reaffirmed a "buy" rating on shares of Lifevantage in a report on Thursday, February 5th. Finally, Weiss Ratings downgraded Lifevantage from a "hold (c)" rating to a "hold (c-)" rating in a research report on Monday. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Lifevantage currently has a consensus rating of "Moderate Buy" and a consensus price target of $5.00.

Insider Transactions at Lifevantage

In other news, Director Judd Dayton purchased 18,097 shares of Lifevantage stock in a transaction that occurred on Friday, February 27th. The stock was bought at an average price of $4.63 per share, with a total value of $83,789.11. Following the completion of the transaction, the director directly owned 69,859 shares of the company's stock, valued at approximately $323,447.17. The trade was a 34.96% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have bought 38,207 shares of company stock valued at $178,585 over the last three months. 21.95% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Lifevantage

A number of hedge funds have recently bought and sold shares of the business. Cetera Investment Advisers grew its position in Lifevantage by 29.4% in the 4th quarter. Cetera Investment Advisers now owns 25,405 shares of the company's stock worth $156,000 after purchasing an additional 5,771 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Lifevantage by 33.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 18,234 shares of the company's stock worth $113,000 after acquiring an additional 4,600 shares during the period. Wells Fargo & Company MN increased its position in Lifevantage by 65.7% during the fourth quarter. Wells Fargo & Company MN now owns 13,134 shares of the company's stock valued at $81,000 after acquiring an additional 5,206 shares during the last quarter. LPL Financial LLC lifted its holdings in Lifevantage by 19.0% in the fourth quarter. LPL Financial LLC now owns 28,303 shares of the company's stock valued at $174,000 after acquiring an additional 4,524 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in Lifevantage by 74.3% in the third quarter. BNP Paribas Financial Markets now owns 10,694 shares of the company's stock worth $104,000 after purchasing an additional 4,559 shares during the last quarter. Hedge funds and other institutional investors own 35.32% of the company's stock.

About Lifevantage

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company's flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.